 |
|
|
| |
Improvement in Fibrosis Parameters Following Treatment With Fixed-Dose Daclatasvir/Asunaprevir/Beclabuvir in Japanese Patients With Chronic HCV GT 1 Infection
|
| |
| |
Reported by Jules Levin
APASL 2017 Feb 15-19 Shanghai, China
Akuta N,1Toyota J,2Karino Y,2Ikeda F,3Ido A,4Tanaka K,5Takaguchi K,6Naganuma A,7Tomita E,8Chayama K,9Fujiyama S,10Inada Y,11Yoshiji H,12Watanabe H,13Ishikawa H,13Zhao Y,14Swenson ES,14Kumada H1
1Toranomon Hospital, Tokyo, Japan; 2Sapporo-Kosei General Hospital, Sapporo, Japan; 3Okayama University, Okayama, Japan; 4Kagoshima University, Kagoshima, Japan; 5Yokohama City University Medical Center, Yokohama, Japan; 6Kagawa Prefectural Central Hospital, Takamatsu City, Japan; 7Takasaki General Medical Center, Takasaki, Japan; 8Gifu Municipal Hospital, Gifu, Japan; 9Hiroshima University, Hiroshima, Japan; 10Kumamoto Shinto General Hospital, Kumamoto, Japan; 11Miyazaki Medical Center Hospital, Miyazaki, Japan; 12Nara Medical University, Kashihara, Japan; 13Bristol-Myers Squibb K. K., Tokyo, Japan; 14Bristol-Myers Squibb, Princeton, NJ, USA.
|
| |
|
|
|
|
|
